OptiNose Inc
NASDAQ:OPTN
Intrinsic Value
OptiNose, Inc. operates as a pharmaceutical company. [ Read More ]
The intrinsic value of one OPTN stock under the Base Case scenario is 2.812 USD. Compared to the current market price of 0.905 USD, OptiNose Inc is Undervalued by 68%.
Valuation Backtest
OptiNose Inc
Run backtest to discover the historical profit from buying and selling OPTN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
OptiNose Inc
Current Assets | 105.3m |
Cash & Short-Term Investments | 73.7m |
Receivables | 19.9m |
Other Current Assets | 11.7m |
Non-Current Assets | 2.4m |
PP&E | 815k |
Other Non-Current Assets | 1.6m |
Current Liabilities | 176.5m |
Accounts Payable | 3.9m |
Accrued Liabilities | 42.4m |
Short-Term Debt | 130.2m |
Non-Current Liabilities | 17.8m |
Other Non-Current Liabilities | 17.8m |
Earnings Waterfall
OptiNose Inc
Revenue
|
71m
USD
|
Cost of Revenue
|
-8.6m
USD
|
Gross Profit
|
62.4m
USD
|
Operating Expenses
|
-85.1m
USD
|
Operating Income
|
-22.7m
USD
|
Other Expenses
|
-12.7m
USD
|
Net Income
|
-35.5m
USD
|
Free Cash Flow Analysis
OptiNose Inc
OPTN Profitability Score
Profitability Due Diligence
OptiNose Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
OptiNose Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
OPTN Solvency Score
Solvency Due Diligence
OptiNose Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Score
OptiNose Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OPTN Price Targets Summary
OptiNose Inc
According to Wall Street analysts, the average 1-year price target for OPTN is 3.825 USD with a low forecast of 3.03 USD and a high forecast of 5.25 USD.
Ownership
OPTN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
OPTN Price
OptiNose Inc
Average Annual Return | -30.66% |
Standard Deviation of Annual Returns | 25.72% |
Max Drawdown | -92% |
Market Capitalization | 101.7m USD |
Shares Outstanding | 112 652 000 |
Percentage of Shares Shorted | 3.19% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 189 full-time employees. The company went IPO on 2017-10-13. The firm's first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), is a therapeutic utilizing the Company's Exhalation Delivery System (EDS), which delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.
Contact
IPO
Employees
Officers
The intrinsic value of one OPTN stock under the Base Case scenario is 2.812 USD.
Compared to the current market price of 0.905 USD, OptiNose Inc is Undervalued by 68%.